Emglev Therapeutics

Emglev Therapeutics is a biotechnology company founded in 2023 as a spin-off from the Curie Institute. It is dedicated to discovering and developing transformative immunotherapies to address unmet medical needs in the field of oncology. By leveraging its unique proprietary platform, the company overcomes current obstacles in traditional antibody discovery to deliver distinctive targets and sdAbs, which are fully selected in vitro and validated for therapeutic applications against any target in any format. The company focuses on advancing immunotherapies to a higher level for the benefit of all patients with significant unmet needs.